1. Home
  2. ALV vs ABVX Comparison

ALV vs ABVX Comparison

Compare ALV & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Autoliv Inc.

ALV

Autoliv Inc.

HOLD

Current Price

$110.66

Market Cap

8.9B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$118.05

Market Cap

9.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALV
ABVX
Founded
1953
2013
Country
Sweden
France
Employees
65200
67
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.9B
9.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ALV
ABVX
Price
$110.66
$118.05
Analyst Decision
Buy
Buy
Analyst Count
10
13
Target Price
$134.40
$131.31
AVG Volume (30 Days)
626.5K
882.8K
Earning Date
04-17-2026
03-23-2026
Dividend Yield
3.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.55
$70.74
Revenue Next Year
$3.47
$3,694.18
P/E Ratio
$13.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$77.73
$5.20
52 Week High
$130.14
$148.83

Technical Indicators

Market Signals
Indicator
ALV
ABVX
Relative Strength Index (RSI) 55.49 52.48
Support Level $99.80 $105.48
Resistance Level $128.33 $130.20
Average True Range (ATR) 2.36 5.76
MACD 1.20 0.83
Stochastic Oscillator 81.94 66.92

Price Performance

Historical Comparison
ALV
ABVX

About ALV Autoliv Inc.

Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: